Somebody at PIQ, perhaps a new director is driving a far better...

Somebody at PIQ, perhaps a new director is driving a far better media strategy than has been seen previously and is having a great effect. Last night the new Endo test results were featured on Channel 7 and Channel 9 news services.

Today we read in The Australian an extensive article on the new Endo test results as well.

Well done to the PR team responsible for this broadening coverage.

****************************************************************************
‘ENDO’ TEST GIVES HOPE TO WOMEN

James Dowling

An Australian blood test for endometriosis raises the prospect of a quicker diagnosis of one of the most common causes of infertility and chronic pain for women, with clinicians heralding attention for the much-overlooked condition.
Endometriosis saddles victims with a seven-year path to diagnosis on average, which is often complicated by its complexity and under-representation in medical research.
A study by the Royal Women’s Hospital and pharma group Proteomics has shown the potential success of a blood test for the condition, which could dramatically streamline the diagnosis and help catch endometriosis before it develops.
The study’s outcomes, published in the peer-reviewed journal Human Reproduction, show statistically significant results in a clinical study of plasma samples from more than 800 participants.
It fills a clinical void, given the international lack of non-invasive endometriosis testing methods.
“This breakthrough is an exciting advance in the diagnosis of this debilitating disease,” Royal Women’s Hospital research director Peter Rogers said.
He urged more stakeholders to invest in endometriosis research and benign gynaecological sciences, given the years of neglect uncovered by the study.
“Women’s health research, particularly in what I call benign gynaecology, has a massive impact on the healthcare of women, and therefore families, therefore the nation, and it is grossly underfunded and grossly under-researched,” he said.
“There’s just no parity between the actual impact on society in the healthcare cost and the resources that are going into it.”
Australia has one of the highest rates of spending per capita on endometriosis, and yet despite affecting a similar proportion of the population as diabetes, it receives a tiny 2.4 per cent of comparative funding.
Albury estate agent Kate McAuley, 29, was diagnosed with stage four endometriosis in 2021 after six years of symptoms. She experienced chronic pain, hospitalisations, and multiple surgeries. Despite a family history of ovarian cancer, her condition was initially dismissed.
“I used to have really horrible periods, to the point where I was even fired from jobs because I couldn’t make it into work sometimes for a couple of days every month,” Ms McAuley said.
“I think about it now, and it is so strange that I wasn’t really checked properly through an ultrasound until much later.”
Following her diagnosis and five subsequent procedures, Ms McAuley was informed she had reached the brink of infertility.
“My specialist ended up calling me in and asked me to bring a support person. She said, “I’ve never had a conversation with somebody this young, but it is my strongest belief that you will not be able to have children in 12 months time, unless you try IVF now”,” she said.
“It was getting to the point where there’s so much scarring … where the next recommendation would be a hysterectomy, just to give me back basically that week of every month that I couldn’t move. But they knew how badly I wanted to be a mum.”
Faced with the ultimatum, Ms McAuley opted to begin IVF with the help of a sperm donor, and she is expecting a baby boy in the coming months.
“If an 18-year-old can get a blood test and find out she has endometriosis before it gets to the point where it’s affecting her fertility, then she has a lot longer to make that decision about what she wants to do,” she said.
Endometriosis affects one in nine Australian women and results in 40,000 hospital admissions annually. White treatable, it is incurable
Proteomics managing director Richard Lipscombe estimated a rollout for the test within the next six months, provided further trials proved it was effective.